Teva Pharmaceutical Industries ROE 2010-2024 | TEVA
Current and historical return on equity (ROE) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Teva Pharmaceutical Industries ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-09-30 |
$-0.96B |
$6.38B |
-13.39% |
| 2024-06-30 |
$-0.45B |
$6.56B |
-6.08% |
| 2024-03-31 |
$-0.48B |
$7.54B |
-6.19% |
| 2023-12-31 |
$-0.56B |
$8.13B |
-7.00% |
| 2023-09-30 |
$-2.34B |
$7.51B |
-28.84% |
| 2023-06-30 |
$-2.35B |
$7.71B |
-27.31% |
| 2023-03-31 |
$-1.71B |
$8.61B |
-18.72% |
| 2022-12-31 |
$-2.45B |
$8.60B |
-25.61% |
| 2022-09-30 |
$-1.29B |
$9.52B |
-12.63% |
| 2022-06-30 |
$-1.05B |
$9.83B |
-9.85% |
| 2022-03-31 |
$-0.62B |
$10.26B |
-5.56% |
| 2021-12-31 |
$0.42B |
$11.24B |
3.71% |
| 2021-09-30 |
$0.73B |
$11.45B |
6.48% |
| 2021-06-30 |
$-3.92B |
$11.31B |
-35.64% |
| 2021-03-31 |
$-3.98B |
$10.98B |
-33.57% |
| 2020-12-31 |
$-3.99B |
$11.06B |
-31.25% |
| 2020-09-30 |
$-4.03B |
$10.59B |
-29.28% |
| 2020-06-30 |
$0.00B |
$14.82B |
0.03% |
| 2020-03-31 |
$-0.83B |
$14.59B |
-5.52% |
| 2019-12-31 |
$-1.00B |
$15.06B |
-6.54% |
| 2019-09-30 |
$-4.05B |
$14.93B |
-26.20% |
| 2019-06-30 |
$-4.01B |
$15.25B |
-24.28% |
| 2019-03-31 |
$-3.56B |
$15.82B |
-20.30% |
| 2018-12-31 |
$-2.40B |
$15.79B |
-12.90% |
| 2018-09-30 |
$-11.06B |
$19.13B |
-57.19% |
| 2018-06-30 |
$-10.26B |
$19.37B |
-46.35% |
| 2018-03-31 |
$-16.05B |
$20.10B |
-65.01% |
| 2017-12-31 |
$-16.53B |
$18.75B |
-57.78% |
| 2017-09-30 |
$-5.96B |
$30.30B |
-18.26% |
| 2017-06-30 |
$-6.15B |
$29.61B |
-17.89% |
| 2017-03-31 |
$0.08B |
$35.75B |
0.22% |
| 2016-12-31 |
$0.07B |
$34.99B |
0.20% |
| 2016-09-30 |
$1.59B |
$37.03B |
4.91% |
| 2016-06-30 |
$1.35B |
$32.02B |
4.66% |
| 2016-03-31 |
$1.70B |
$30.59B |
6.37% |
| 2015-12-31 |
$1.57B |
$29.93B |
6.38% |
| 2015-09-30 |
$1.78B |
$22.90B |
7.72% |
| 2015-06-30 |
$2.55B |
$23.09B |
10.98% |
| 2015-03-31 |
$2.76B |
$22.68B |
11.82% |
| 2014-12-31 |
$3.06B |
$23.36B |
13.05% |
| 2014-09-30 |
$2.75B |
$23.67B |
11.83% |
| 2014-06-30 |
$2.58B |
$23.59B |
11.27% |
| 2014-03-31 |
$1.38B |
$23.03B |
6.17% |
| 2013-12-31 |
$1.27B |
$22.64B |
5.67% |
| 2013-09-30 |
$1.21B |
$22.39B |
5.39% |
| 2013-06-30 |
$0.42B |
$21.61B |
1.85% |
| 2013-03-31 |
$1.73B |
$22.81B |
7.57% |
| 2012-12-31 |
$1.96B |
$22.87B |
8.53% |
| 2012-09-30 |
$2.15B |
$23.07B |
9.39% |
| 2012-06-30 |
$3.14B |
$22.89B |
13.76% |
| 2012-03-31 |
$2.86B |
$23.20B |
12.39% |
| 2011-12-31 |
$2.76B |
$22.34B |
11.97% |
| 2011-09-30 |
$3.02B |
$22.94B |
13.17% |
| 2011-06-30 |
$3.16B |
$23.75B |
13.94% |
| 2011-03-31 |
$3.38B |
$23.13B |
15.68% |
| 2010-12-31 |
$3.33B |
$22.00B |
16.10% |
| 2010-09-30 |
$2.94B |
$21.71B |
14.69% |
| 2010-06-30 |
$2.54B |
$19.36B |
13.08% |
| 2010-03-31 |
$2.26B |
$19.68B |
11.89% |
| 2009-12-31 |
$2.00B |
$19.26B |
11.03% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.044B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
